Insights Into the Pathology and Treatment of Spondyloarthritis: From the Bench to the Clinic

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 2, 2008, Pages 83-100

  Davis Jr , John C ^a   Mease, Philip J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Seattle Rhumatology Associates   (United States)

Author keywords

ankylosing spondylitis; psoriatic arthritis; spondyloarthritis; tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; ETANERCEPT; HLA B27 ANTIGEN; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOPENIA; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERITIS; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; LUPUS VULGARIS; META ANALYSIS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REACTIVE ARTHRITIS; SPONDYLOARTHROPATHY; SPONDYLOSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-B27 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; TREATMENT OUTCOME;

EID: 52149084828     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.10.007     Document Type: Article

References (191)

1. Kataria R.K., and Brent L.H. Spondyloarthropathies. Am Fam Physician 69 (2004) 2853-2860
2. Nash P., Mease P.J., Braun J., and van der Heijde D. Seronegative spondyloarthropathies: to lump or split?. Ann Rheum Dis 64 (2005) ii9-ii13
3. van der Linden S., Valkenburg H.A., and Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 (1984) 361-368
4. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34 (1991) 1218-1227
5. Amor B., Dougados M., and Mijiyawa M. [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic 57 (1990) 85-89
6. Moll J.M., and Wright V. Psoriatic arthritis. Semin Arthritis Rheum 3 (1973) 55-78
7. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., and Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006) 2665-2673
8. Helliwell P.S., and Taylor W.J. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 64 (2005) ii3-ii8
9. Rudwaleit M., van der Heijde D., Khan M.A., Braun J., and Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 63 (2004) 535-543
10. Rudwaleit M., Khan M.A., and Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum 52 (2005) 1000-1008
11. Heuft-Dorenbosch L., Landewe R., Weijers R., Houben H., van der Linden S., Jacobs P., et al. Performance of various criteria sets in patients with inflammatory back pain of short duration: the Maastricht early spondyloarthritis clinic. Ann Rheum Dis 66 (2007) 92-98
12. Brewerton D.A., Hart F.D., Nicholls A., Caffrey M., James D.C., and Sturrock R.D. Ankylosing spondylitis and HL-A 27. Lancet 1 (1973) 904-907
13. Schlosstein L., Terasaki P.I., Bluestone R., and Pearson C.M. High association of an HL-A antigen. W27, with ankylosing spondylitis. N Engl J Med 288 (1973) 704-706
14. Khan M.A., and Ball E.J. Genetic aspects of ankylosing spondylitis. Best Pract Res Clin Rheumatol 16 (2002) 675-690
15. Brown M.A., Pile K.D., Kennedy L.G., Calin A., Darke C., Bell J., et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 55 (1996) 268-270
16. Khan M.A., Braun W.E., Kushner I., Grecek D.E., Muir W.A., and Steinberg A.G. HLA B27 in ankylosing spondylitis: differences in frequency and relative risk in American Blacks and Caucasians. J Rheumatol Suppl 3 (1977) 39-43
17. Reveille J.D. The genetic basis of spondyloarthritis. Curr Rheumatol Rep 6 (2004) 117-125
18. Marsal S., Armadans-Gil L., Martinez M., Gallardo D., Ribera A., and Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 38 (1999) 332-337
19. Queiro R., Sarasqueta C., Belzunegui J., Gonzalez C., Figueroa M., and Torre-Alonso J.C. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum 31 (2002) 413-418
20. Tsai Y.G., Chang D.M., Kuo S.Y., Wang W.M., Chen Y.C., and Lai J.H. Relationship between human lymphocyte antigen-B27 and clinical features of psoriatic arthritis. J Microbiol Immunol Infect 36 (2003) 101-104
21. Hillig R.C., Hulsmeyer M., Saenger W., Welfle K., Misselwitz R., Welfle H., et al. Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association. J Biol Chem 279 (2004) 652-663
22. Khan M.A. Update: the twenty subtypes of HLA-B27. Curr Opin Rheumatol 12 (2000) 235-238
23. Ramos M., Paradela A., Vazquez M., Marina A., Vazquez J., and Lopez de Castro J.A. Differential association of HLA-B*2705 and B*2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability. J Biol Chem 277 (2002) 28749-28756
24. Boyle L.H., Goodall J.C., Opat S.S., and Gaston J.S. The recognition of HLA-B27 by human CD4(+) T lymphocytes. J Immunol 167 (2001) 2619-2624
25. Roddis M., Carter R.W., Sun M.Y., Weissensteiner T., McMichael A.J., Bowness P., et al. Fully functional HLA B27-restricted CD4+ as well as CD8+ T cell responses in TCR transgenic mice. J Immunol 172 (2004) 155-161
26. Ebringer A., Ahmadi K., Fielder M., Rashid T., Tiwana H., Wilson C., et al. Molecular mimicry: the geographical distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy. Clin Rheumatol 15 suppl 1 (1996) 57-61
27. Eulderink F., Ivanyi P., and Weinreich S. Histopathology of murine ankylosing enthesopathy. Pathol Res Pract 194 (1998) 797-803
28. Weinreich S., Eulderink F., Capkova J., Pla M., Gaede K., Heesemann J., et al. HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. Hum Immunol 42 (1995) 103-115
29. Rehakova Z., Capkova J., Stepankova R., Sinkora J., Louzecka A., Ivanyi P., et al. Germ-free mice do not develop ankylosing enthesopathy, a spontaneous joint disease. Hum Immunol 61 (2000) 555-558
30. Weinreich S., Hoebe-Hewryk B., Boog C., and Ivanyi P. Solitary caging protects mice from ankylosing enthesopathy. Clin Rheumatol 15 (1996) 32-33
31. Taurog J.D., Richardson J.A., Croft J.T., Simmons W.A., Zhou M., Fernandez-Sueiro J.L., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180 (1994) 2359-2364
32. Rath H.C. Role of commensal bacteria in chronic experimental colitis: lessons from the HLA-B27 transgenic rat. Pathobiology 70 (2002) 131-138
33. Brown M.A., Kennedy L.G., MacGregor A.J., Darke C., Duncan E., Shatford J.L., et al. Susceptibility to ankylosing spondylitis in twins: the role of genes. HLA, and the environment Arthritis Rheum 40 (1997) 1823-1828
34. Rubin L.A., Amos C.I., Wade J.A., Martin J.R., Bale S.J., Little A.H., et al. Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. Arthritis Rheum 37 (1994) 1212-1220
35. Rahman P., and Elder J.T. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64 suppl 2 (2005) ii37-ii39 discussion ii40-1
36. Sims A.M., Wordsworth B.P., and Brown M.A. Genetic susceptibility to ankylosing spondylitis. Curr Mol Med 4 (2004) 13-20
37. Khan M.A., Mathieu A., Sorrentino R., and Akkoc N. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev 6 (2007) 183-189
38. Breban M. Genetics of spondyloarthritis. Best Pract Res Clin Rheumatol 20 (2006) 593-599
39. Baeten D., Kruithof E., De Rycke L., Boots A.M., Mielants H., Veys E.M., et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 7 (2005) R359-R369
40. Kruithof E., Baeten D., De Rycke L., Vandooren B., Foell D., Roth J., et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 7 (2005) R569-R580
41. Costello P.J., Winchester R.J., Curran S.A., Peterson K.S., Kane D.J., Bresnihan B., et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 166 (2001) 2878-2886
42. Dulphy N., Peyrat M.A., Tieng V., Douay C., Rabian C., Tamouza R., et al. Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27. J Immunol 162 (1999) 3830-3839
43. Duftner C., Goldberger C., Falkenbach A., Wurzner R., Falkensammer B., Pfeiffer K.P., et al. Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis. Arthritis Res Ther 5 (2003) R292-R300
44. Martin M.P., Nelson G., Lee J.H., Pellett F., Gao X., Wade J., et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169 (2002) 2818-2822
45. Shi S., Ciurli C., Cartman A., Pidoux I., Poole A.R., and Zhang Y. Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum 48 (2003) 2903-2915
46. Zou J., Zhang Y., Thiel A., Rudwaleit M., Shi S.L., Radbruch A., et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 42 (2003) 846-855
47. Danning C.L., Illei G.G., Hitchon C., Greer M.R., Boumpas D.T., and McInnes I.B. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43 (2000) 1244-1256
48. Fraser A., Fearon U., Billinghurst R.C., Ionescu M., Reece R., Barwick T., et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 48 (2003) 3085-3095
49. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38 (1995) 499-505
50. Partsch G., Steiner G., Leeb B.F., Dunky A., Broll H., and Smolen J.S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24 (1997) 518-523
51. Hitchon C.A., Danning C.L., Illei G.G., El-Gabalawy H.S., and Boumpas D.T. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. J Rheumatol 29 (2002) 107-117
52. Vandooren B., Kruithof E., Yu D.T., Rihl M., Gu J., De Rycke L., et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50 (2004) 2942-2953
53. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., and Schwarz E.M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111 (2003) 821-831
54. Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63 (2004) 755-758
55. Gottlieb A.B. Infliximab for psoriasis. J Am Acad Dermatol 49 (2003) S112-S117
56. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355 (2006) 704-712
57. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
58. Goedkoop A.Y., Kraan M.C., Teunissen M.B., Picavet D.I., de Rie M.A., Bos J.D., et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 63 (2004) 769-773
59. De Rycke L., Vandooren B., Kruithof E., De Keyser F., Veys E.M., and Baeten D. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 52 (2005) 2146-2158
60. Zenz R., Eferl R., Kenner L., Florin L., Hummerich L., Mehic D., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437 (2005) 369-375
61. van der Heijde D., Dougados M., Davis J., Weisman M.H., Maksymowych W., Braun J., et al. ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 52 (2005) 386-394
62. van der Heijde D., Calin A., Dougados M., Khan M.A., van der Linden S., and Bellamy N. Selection of instruments in the core set for DC-ART. SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis Progress report of the ASAS Working Group Assessments in Ankylosing Spondylitis J Rheumatol 26 (1999) 951-954
63. Braun J., and Sieper J. Ankylosing spondylitis. Lancet 369 (2007) 1379-1390
64. Boulos P., Dougados M., Macleod S.M., and Hunsche E. Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 65 (2005) 2111-2127
65. Zochling J., van der Heijde D., Dougados M., and Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65 (2006) 423-432
66. Zochling J., van der Heijde D., Burgos-Vargas R., Collantes E., Davis Jr. J.C., Dijkmans B., et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65 (2006) 442-452
67. Mease P.J., Antoni C.E., Gladman D.D., and Taylor W.J. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64 suppl 2 (2005) ii49-ii54
68. Turkiewicz A.M., and Moreland L.W. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 56 (2007) 1051-1066
69. Kavanaugh A.F., and Ritchlin C.T. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 33 (2006) 1417-1421
70. Soriano E.R., and McHugh N.J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33 (2006) 1422-1430
71. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 33 (2006) 1431-1434
72. Dougados M., Dijkmans B., Khan M., Maksymowych W., van der Linden S., and Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61 (2002) iii40-iii50
73. Dagfinrud H., Kvien T.K., and Hagen K.B. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev (2004) CD002822
74. van Tubergen A., Boonen A., Landewe R., Rutten-Van Molken M., Van Der Heijde D., Hidding A., et al. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 47 (2002) 459-467
75. van Tubergen A., and Hidding A. Spa and exercise treatment in ankylosing spondylitis: fact or fancy?. Best Pract Res Clin Rheumatol 16 (2002) 653-666
76. Hakkinen A., Hakkinen K., and Hannonen P. Effects of strength training on neuromuscular function and disease activity in patients with recent-onset inflammatory arthritis. Scand J Rheumatol 23 (1994) 237-242
77. Miceli-Richard C., and Dougados M. NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 20 (2002) S65-S66
78. Wanders A., Heijde D., Landewe R., Behier J.M., Calin A., Olivieri I., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52 (2005) 1756-1765
79. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
80. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
81. Simon L.S., and Strand V. Perception of risk: the state of COX-2 selective inhibitors. Curr Rheumatol Rep 7 (2005) 163-166
82. Nash P., and Clegg D.O. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64 (2005) ii74-ii77
83. Braun J., Baraliakos X., Godolias G., and Bohm H. Therapy of ankylosing spondylitis-a review. Part I: conventional medical treatment and surgical therapy. Scand J Rheumatol 34 (2005) 97-108
84. Christophers E., and Mrowietz U. Fitzpatrick's Dermatology in General Medicine (1999), McGraw Hill, New York
85. Witman P.M. Topical therapies for localized psoriasis. Mayo Clin Proc 76 (2001) 943-949
86. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38 (1995) 618-627
87. Clegg D.O., Reda D.J., and Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42 (1999) 2325-2329
88. Jones G., Crotty M., and Brooks P. Interventions for psoriatic arthritis. Cochrane Database of Systematic Reviews (2000) CD000212
89. Clegg D.O., Reda D.J., Mejias E., Cannon G.W., Weisman M.H., Taylor T., et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39 (1996) 2013-2020
90. Farr M., Kitas G.D., Waterhouse L., Jubb R., Felix-Davies D., and Bacon P.A. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 29 (1990) 46-49
91. Gupta A.K., Grober J.S., Hamilton T.A., Ellis C.N., Siegel M.T., Voorhees J.J., et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 22 (1995) 894-898
92. Fraser S.M., Hopkins R., Hunter J.A., Neumann V., Capell H.A., and Bird H.A. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 32 (1993) 923-925
93. Rahman P., Gladman D.D., Cook R.J., Zhou Y., and Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 25 (1998) 1957-1961
94. Kane D., Gogarty M., O'Leary J., Silva I., Bermingham N., Bresnihan B., et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 50 (2004) 3286-3295
95. Iagnocco A., Cerioni A., Coari G., Ossandon A., Masciangelo R., and Valesini G. Intra-articular methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis: a clinical and sonographic study. Clin Rheumatol (2005) [Epub ahead of print]
96. Willkens R.F., Williams H.J., Ward J.R., Egger M.J., Reading J.C., Clements P.J., et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 27 (1984) 376-381
97. Abu-Shakra M., Gladman D.D., Thorne J.C., Long J., Gough J., and Farewell V.T. Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 22 (1995) 241-245
98. Salvarani C., Macchioni P., Olivieri I., Marchesoni A., Cutolo M., Ferraccioli G., et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28 (2001) 2274-2282
99. Kaltwasser J.P., Nash P., Gladman D., Rosen C.F., Behrens F., Jones P., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50 (2004) 1939-1950
100. Gonzalez-Lopez L., Garcia-Gonzalez A., Vazquez-Del-Mercado M., Munoz-Valle J.F., and Gamez-Nava J.I. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31 (2004) 1568-1574
101. Biasi D., Carletto A., Caramaschi P., Pacor M.L., Maleknia T., and Bambara L.M. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 19 (2000) 114-117
102. Haibel H., Brandt H.C., Song I.H., Brandt A., Listing J., Rudwaleit M., et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66 (2007) 419-421
103. Chen J., and Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev (2004) CD004524
104. Chen J., and Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev (2005) CD004800.
105. Hanauer S.B., and Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 6 (1991) 192-219
106. Haibel H., Rudwaleit M., Braun J., and Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 64 (2005) 124-126
107. Van Denderen J.C., Van der Paardt M., Nurmohamed M.T., De Ryck Y.M., Dijkmans B.A., and Van der Horst-Bruinsma I.E. Double-blind, randomised, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis (2005) [Epub ahead of print]
108. Maksymowych W.P., Jhangri G.S., Leclercq S., Skeith K., Yan A., and Russell A.S. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 25 (1998) 714-717
109. Cairns A.P., Wright S.A., Taggart A.J., Coward S.M., and Wright G.D. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 64 (2005) 338-339
110. Maksymowych W.P., Jhangri G.S., Fitzgerald A.A., LeClercq S., Chiu P., Yan A., et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46 (2002) 766-773
111. Haibel H., Brandt J., Rudwaleit M., Soerensen H., Sieper J., and Braun J. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) 42 (2003) 1018-1020
112. Sullivan K.E. Regulation of inflammation. Immunol Res 27 (2003) 529-538
113. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
114. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50 (2004) 2264-2272
115. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33 (2006) 712-721
116. Gorman J.D., Sack K.E., and Davis Jr. J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346 (2002) 1349-1356
117. Davis Jr. J., Webb A., Lund S., and Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum 51 (2004) 302-304
118. Braun J., Pham T., Sieper J., Davis J., van der Linden S., Dougados M., et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62 (2003) 817-824
119. Calin A., Dijkmans B.A., Emery P., Hakala M., Kalden J., Leirisalo-Repo M., et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63 (2004) 1594-1600
120. Davis J.C., van der Heijde D.M., Braun J., Dougados M., Cush J., Clegg D., et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64 (2005) 1557-1562
121. Baraliakos X., Davis J., Tsuji W., and Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52 (2005) 1216-1223
122. Rudwaleit M., Baraliakos X., Listing J., Brandt J., Sieper J., and Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 64 (2005) 1305-1310
123. Brandt J., Khariouzov A., Listing J., Haibel H., Sorensen H., Rudwaleit M., et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 31 (2004) 531-538
124. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52 (2005) 1227-1236
125. Kavanaugh A., Antoni C.E., Gladman D., Wassenberg S., Zhou B., Beutler A., et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65 (2006) 1038-1043
126. Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64 (2005) 1150-1157
127. van der Heijde D., Kavanaugh A., Beutler A., Guzzo C., Zhou B., Dooley L., et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: results from IMPACT 2 trial. Ann Rheum Dis (2005) 64109
128. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70 (2002) 11-19
129. Braun J., Baraliakos X., Brandt J., Listing J., Zink A., Alten R., et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44 (2005) 670-676
130. Baraliakos X., Listing J., Rudwaleit M., Brandt J., Sieper J., and Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 64 (2005) 1462-1466
131. van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52 (2005) 582-591
132. Brandt J., Haibel H., Reddig J., Sieper J., and Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29 (2002) 118-122
133. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
134. Davis Jr. J.C., and Gladman D.D. Spinal mobility measures in spondyloarthritis: application of the OMERACT filter. J Rheumatol 34 (2007) 666-670
135. van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A., Braun J., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54 (2006) 2136-2146
136. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
137. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
138. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
139. Rosenbaum J.T., and Smith J.R. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 20 (2002) S143-S145
140. Suhler E.B., Smith J.R., Wertheim M.S., Lauer A.K., Kurz D.E., Pickard T.D., et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123 (2005) 903-912
141. Aletaha D., Kapral T., and Smolen J.S. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 62 (2003) 482-486
142. Fleischmann R.M., Iqbal I., and Stern R.L. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 3 (2004) 391-403
143. Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003) 1315-1324
144. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44 (2005) 714-720
145. Overview of ASAS and US modifications of the ASAS guidelines. http://www.spondylitis.org/physician_resources/guidelines aspx accessed August 5, 2005
146. Caproni M., Torchia D., Cardinali C., Volpi W., Del Bianco E., D'Agata A., et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol 151 (2004) 784-791
147. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 15 (2004) 280-294
148. Afifi T., de Gannes G., Huang C., and Zhou Y. Topical therapies for psoriasis: evidence-based review. Can Fam Physician 51 (2005) 519-525
149. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007) 629-634
150. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144 (2006) 865-876
151. Amevive® (alefacept). Full Prescribing Information, Biogen, Cambridge, MA, 2005.
152. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
153. Mease P.J., Gladman D.D., and Keystone E.C. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 54 (2006) 1638-1645
154. Papp K., Caro I., Leung H.M., Garovoy M., and Mease P.J. Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo controlled study (2004), International Psoriasis Symposium, Toronto, Canada
155. Gibbs A., Gogarty M., Bresnahan B., Gibney R., Veale D., and Fitzgerald O. Moderate clinical response and absence of MRI or immunohistological change suggest that anakinra is ineffective in psoriatic arthritis [abstract]. Arthritis and Rheum 54 suppl 9 (2006) S719
156. Haibel H., Rudwaleit M., Listing J., and Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64 (2005) 296-298
157. McInnes I.B., Gracie J.A., Harnett M., Harnett W., and Liew F.Y. New strategies to control inflammatory synovitis: interleukin 15 and beyond. Ann Rheum Dis 62 (2003) ii51-ii54
158. Nishimoto N., Kishimoto T., and Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59 (2000) i21-i27
159. Keystone E.C. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology (Oxford) 44 (2005) ii8-ii12
160. Krueger G., Langley R., Leonardi C., and Lebwhol M. Results of a phase II study of CNTO 1275 in the treatment of psoriasis [abstract]. J Am Acad Dermatol 54 suppl 3 (2006) AB10
161. Pham T., van der Heijde D., Calin A., Khan M.A., van der Linden S., Bellamy N., et al. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis 62 (2003) 812-816
162. USAS Consensus Chart. http://www.spartangroup.org/ accessed September 8, 2005
163. Kyle S., Chandler D., Griffiths C.E., Helliwell P., Lewis J., McInnes I., et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 44 (2005) 390-397
164. Sieper J., Braun J., Rudwaleit M., Boonen A., and Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 61 (2002) iii8-iii18
165. Gladman D.D., Antoni C., Mease P., Clegg D.O., and Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 suppl 2 (2005) ii14-ii17
166. Palazzi C., Olivieri I., D'Amico E., Pennese E., and Petricca A. Management of reactive arthritis. Exp Opin Pharmacother 5 (2004) 61-70
167. Olivieri I., Salvarani C., Cantini F., Ciancio G., and Padula A. Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol 13 (2001) 280-284
168. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41 (1998) 58-67
169. McGarry K.A., and Kiel D.P. Postmenopausal osteoporosis strategies for preventing bone loss, avoiding fracture. Postgrad Med 108 (2000) 79-82 85-8, 91
170. van der Paardt M., Crusius J.B., Garcia-Gonzalez M.A., Baudoin P., Kostense P.J., Alizadeh B.Z., et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford) 41 (2002) 1419-1423
171. Timms A.E., Crane A.M., Sims A.M., Cordell H.J., Bradbury L.A., Abbott A., et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 75 (2004) 587-595
172. Tsui F.W., Tsui H.W., Cheng E.Y., Stone M., Payne U., Reveille J.D., et al. Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 48 (2003) 791-797
173. Balding J., Kane D., Livingstone W., Mynett-Johnson L., Bresnihan B., Smith O., et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 48 (2003) 1408-1413
174. Ravindran J.S., Owen P., Lagan A., Lewis J., Korendowych E., Welsh K., et al. Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. Rheumatology (Oxford) 43 (2004) 22-26
175. Rahman P., Bartlett S., Siannis F., Pellett F.J., Farewell V.T., Peddle L., et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet 73 (2003) 677-681
176. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80 (2007) 273-290
177. Crane A.M., Bradbury L., van Heel D.A., McGovern D.P., Brophy S., Rubin L., et al. Role of NOD2 variants in spondyloarthritis. Arthritis Rheum 46 (2002) 1629-1633
178. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
179. Gu J., Marker-Hermann E., Baeten D., Tsai W.C., Gladman D., Xiong M., et al. A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) 41 (2002) 759-766
180. Baraliakos X., Landewe R., Hermann K.G., Listing J., Golder W., Brandt J., et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 64 (2005) 730-734
181. van der Heijde D.M., Landewe R.B., Hermann K.G., Jurik A.G., Maksymowych W.P., Rudwaleit M., et al. Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7. J Rheumatol 32 (2005) 2042-2047
182. Maksymowych W.P., Inman R.D., Salonen D., Dhillon S.S., Williams M., Stone M., et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 53 (2005) 703-709
183. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
184. Clegg D.O., Reda D.J., Weisman M.H., Blackburn W.D., Cush J.J., Cannon G.W., et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39 (1996) 2004-2012
185. van Gestel A.M., Anderson J.J., van Riel P.L., Boers M., Haagsma C.J., Rich B., et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 26 (1999) 705-711
186. Fredriksson T., and Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157 (1978) 238-244
187. Feldman S.R., and Krueger G.G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64 suppl 2 (2005) ii65-ii68 discussion ii69-73.
188. Fries J.F., Spitz P., Kraines R.G., and Holman H.R. Measurement of patient outcome in arthritis. Arthritis Rheum 23 (1980) 137-145
189. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
190. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994) 210-216
191. Mease P., and van der Heijde D. Joint damage in psoriatic arthritis: how is it assessed and can it be prevented?. Int J Adv Rheumatol 4 (2006) 38-48